RT Journal Article
SR Electronic
T1 Efficacy of Tegafur-Uracil in Advanced Urothelial Cancer Patients after the Treatment Failure of Platinum-based Chemotherapy
JF Anticancer Research
JO Anticancer Res
FD International Institute of Anticancer Research
SP 1603
OP 1606
VO 35
IS 3
A1 AERKEN MAOLAKE
A1 KOUJI IZUMI
A1 RIE TAKAHASHI
A1 SHINGO ITAI
A1 KAZUAKI MACHIOKA
A1 HIROSHI YAEGASHI
A1 TAKAHIRO NOHARA
A1 YASUHIDE KITAGAWA
A1 YOSHIFUMI KADONO
A1 HIROYUKI KONAKA
A1 ATSUSHI MIZOKAMI
A1 MIKIO NAMIKI
YR 2015
UL http://ar.iiarjournals.org/content/35/3/1603.abstract
AB Background: Platinum-based chemotherapy is the first-line treatment for advanced urinary tract urothelial cancers. However, the optimal second-line treatment is unclear. Although tegafur-uracil is sometimes used for advanced urothelial cancer patients after the treatment failure of platinum-based chemotherapy, there is little evidence regarding its use as a second-line treatment. Patients and Methods: Advanced urothelial cancer patients previously treated with platinum-based chemotherapy were retrospectively analyzed. Overall survival (OS) was compared between patients with and without tegafur-uracil treatment. Results: Thirty-one patients (27 and 4 patients with and without tegafur-uracil treatment, respectively) were analyzed. OS from the last day of the final chemotherapy course was better in patients with tegafur-uracil treatment than in those without (p<0.001, 358 and 66.5 days of the median survival time, respectively). Conclusion: Tegafur-uracil may be a candidate for the secondary treatment of advanced urothelial cancer patients after the treatment failure of platinum-based chemotherapy.